

REMARKS

In the Amendment Under 37 C.F.R. §1.111, filed in this application on November 6, 2003, Applicants refer to support for a utility of the instant invention (as an anti-inflammatory) in the Japanese priority document (JP-A-9-274673).

Enclosed herewith is a sworn translation into English of the Japanese priority document. The referenced discussion may be found at page 16, line 25, through page 17, line 2, of the translation.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: November 17, 2003